Skip to content
Open access · OA via OpenAlex

Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study

Karol Mateusz Pencina, Rodrigo J. Valderrábano, Benjamin Wipper, Ariela R. Orkaby, Kieran F. Reid, Thomas W. Storer, Alexander Peter Lin, Sai K. Merugumala, Lauren A. Wilson, Nancy K. Latham, Catherine Ghattas, Noelle Ozimek, Ming Soon Cheng, Avantika Bhargava, Yusnie M. Beleva

The Journal of Clinical Endocrinology & Metabolism · 2023 · ▲ 47 citations

Abstract

CONTEXT: Nicotinamide adenine dinucleotide (NAD) levels decline with aging and age-related decline in NAD has been postulated to contribute to age-related diseases. OBJECTIVE: We evaluated the safety and physiologic effects of NAD augmentation by administering its precursor, β-nicotinamide mononucleotide (MIB-626, Metro International Biotech, Worcester, MA), in adults at risk for age-related conditions. METHODS: Thirty overweight or obese adults, ≥ 45 years, were randomized in a 2:1 ratio to 2 MIB-626 tablets each containing 500 mg of microcrystalline β-nicotinamide mononucleotide or placebo twice daily for 28 days. Study outcomes included safety; NAD and its metabolome; body weight; liver, muscle, and intra-abdominal fat; insulin sensitivity; blood pressure; lipids; physical performance, and muscle bioenergetics. RESULTS: Adverse events were similar between groups. MIB-626 treatment substantially increased circulating concentrations of NAD and its metabolites. Body weight (difference -1.9 [-3.3, -0.5] kg, P = .008); diastolic blood pressure (difference -7.01 [-13.44, -0.59] mmHg, P = .034); total cholesterol (difference -26.89 [-44.34, -9.44] mg/dL, P = .004), low-density lipoprotein (LDL) cholesterol (-18.73 [-31.85, -5.60] mg/dL, P = .007), and nonhigh-density lipoprotein cholesterol decreased significantly more in the MIB-626 group than placebo. Changes in muscle strength, muscle fatigability, aerobic capacity, and stair-climbing power did not differ significantly between groups. Insulin sensitivity and hepatic and intra-abdominal fat did not change in either group. CONCLUSIONS: MIB-626 administration in overweight or obese, middle-aged and older adults safely increased circulating NAD levels, and significantly reduced total LDL and non-HDL cholesterol, body weight, and diastolic blood pressure. These data provide the rationale for larger trials to assess the efficacy of NAD augmentation in improving cardiometabolic outcomes in older adults.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1210/clinem/dgad027
Canonical
link ↗
Fetched
2026-10-31 MST

Cite this

APA
Pencina, K.M., Valderrábano, R.J., Wipper, B., Orkaby, A.R., Reid, K.F., Storer, T.W., Lin, A.P., Merugumala, S.K., Wilson, L.A., Latham, N.K., Ghattas, C., Ozimek, N., Cheng, M.S., Bhargava, A., Beleva, Y.M., Lawney, B.P., Lavu, S., Swain, P.M., Apte, R.S., &amp; Sinclair, D.A. (2023). Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. <em>The Journal of Clinical Endocrinology & Metabolism</em>. https://doi.org/10.1210/clinem/dgad027
Vancouver
Pencina KM, Valderrábano RJ, Wipper B, Orkaby AR, Reid KF, Storer TW, et al. Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad027.
BibTeX
@article{karol2023Nicoti, title = {Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study}, author = {Karol Mateusz Pencina and Rodrigo J. Valderrábano and Benjamin Wipper and Ariela R. Orkaby and Kieran F. Reid and Thomas W. Storer and Alexander Peter Lin and Sai K. Merugumala and Lauren A. Wilson and Nancy K. Latham and Catherine Ghattas and Noelle Ozimek and Ming Soon Cheng and Avantika Bhargava and Yusnie M. Beleva and Brian P. Lawney and Siva Lavu and Pamela M. Swain and Rajendra S. Apte and David A. Sinclair and David H. Livingston and Shalender Bhasin}, journal = {The Journal of Clinical Endocrinology & Metabolism}, year = {2023}, doi = {10.1210/clinem/dgad027}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings